Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

ABSTRACT:

Background

TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation.

Patients and methods

After imputation of missing at random data, a subset of patients accrued in phase 3 trials with adjuvant chemotherapy (n = 3016)-N0147 (NCT00079274) and PETACC3 (NCT00026273)-was aggregated to construct multivariable Cox models for 5-year overall survival that were subsequently validated internally in the remaining clinical trial samples (n = 1499), and also externally in different population coho

SUBMITTER: Dienstmann R 

PROVIDER: S-EPMC5406760 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature